BioCentury | May 8, 2020
Product Development

Japanese approval for Gilead’s remdesivir

...Biologics Inc. (NASDAQ:ADMA), BioPharma Plasma, GC Pharma and Sanquin. Existing members include Biotest AG (Xetra:BIO), Bio Products Laboratory Ltd....
BioCentury | Apr 30, 2020
Product Development

Alliance advancing unbranded hyperimmune globulin product for COVID-19

...CSL and Takeda are co-leading the CoVIg-19 Plasma Alliance. Other members include Biotest AG (Xetra:BIO), Bio Products Laboratory Ltd....
...crisis can be found at https://www.biocentury.com/coronavirus . Steve Usdin, Washington Editor CSL Ltd. Takeda Pharmaceutical Co. Ltd. Octapharma AG Biotest AG Bio Products Laboratory Ltd. LFB...
BioCentury | Apr 7, 2020
Product Development

COVID-19 roundup: Inovio starts vaccine trial; plus updates from RedHill, Hope, CytoDyn, Gilead, Takeda, AACR and UNC-Emory

...was up $0.70 to $8.44 Monday. Four companies join Takeda-CSL plasma initiative Biotest AG (Xetra:BIO), Bio Products Laboratory Ltd....
...receptor 5 SPHK2 - Sphingosine kinase 2 Elizabeth S. Eaton, Staff Writer Yeliva (opaganib, ABC294640) Inovio Pharmaceuticals Inc. Biotest AG Bio Products Laboratory Ltd. LFB...
BioCentury | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

...chief compliance officer. Vollins was VP, general counsel and director of compliance and secretary at Bio Products Laboratory Ltd....
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
BioCentury | Apr 4, 2016
Clinical News

Coagadex regulatory update

...Factor X protein therapy in Factor X-deficient patients ages >=12 (see BioCentury, Oct. 26, 2015). Bio Products Laboratory Ltd....
BioCentury | Feb 8, 2016
Clinical News

Coagadex regulatory update

...Factor X protein therapy in Factor X-deficient patients ages >=12 (see BioCentury, Oct. 26, 2015). Bio Products Laboratory Ltd....
BioCentury | Feb 1, 2016
Company News

Bio Products Laboratory sales and marketing update

...Late last year, Bio Products Laboratory launched Coagadex in the U.S. for on-demand treatment and control of bleeding...
...acquisition cost (WAC) for the plasma-derived Factor X protein therapy is $7.74 per 1 IU. Bio Products Laboratory Ltd....
BioCentury | Jan 30, 2016
Company News

CHMP backs basket of therapies

...treatment last month (see BioCentury Extra, Dec. 22, 2015) . The committee recommended Coagadex from Bio Products Laboratory Ltd....
BioCentury | Oct 26, 2015
Clinical News

Coagadex regulatory update

...An MAA for the plasma-derived Factor X protein therapy is under review in the EU. Bio Products Laboratory Ltd....
Items per page:
1 - 10 of 16
BioCentury | May 8, 2020
Product Development

Japanese approval for Gilead’s remdesivir

...Biologics Inc. (NASDAQ:ADMA), BioPharma Plasma, GC Pharma and Sanquin. Existing members include Biotest AG (Xetra:BIO), Bio Products Laboratory Ltd....
BioCentury | Apr 30, 2020
Product Development

Alliance advancing unbranded hyperimmune globulin product for COVID-19

...CSL and Takeda are co-leading the CoVIg-19 Plasma Alliance. Other members include Biotest AG (Xetra:BIO), Bio Products Laboratory Ltd....
...crisis can be found at https://www.biocentury.com/coronavirus . Steve Usdin, Washington Editor CSL Ltd. Takeda Pharmaceutical Co. Ltd. Octapharma AG Biotest AG Bio Products Laboratory Ltd. LFB...
BioCentury | Apr 7, 2020
Product Development

COVID-19 roundup: Inovio starts vaccine trial; plus updates from RedHill, Hope, CytoDyn, Gilead, Takeda, AACR and UNC-Emory

...was up $0.70 to $8.44 Monday. Four companies join Takeda-CSL plasma initiative Biotest AG (Xetra:BIO), Bio Products Laboratory Ltd....
...receptor 5 SPHK2 - Sphingosine kinase 2 Elizabeth S. Eaton, Staff Writer Yeliva (opaganib, ABC294640) Inovio Pharmaceuticals Inc. Biotest AG Bio Products Laboratory Ltd. LFB...
BioCentury | Oct 30, 2018
Company News

Management tracks: Blueprint, Clovis

...chief compliance officer. Vollins was VP, general counsel and director of compliance and secretary at Bio Products Laboratory Ltd....
BioCentury | Dec 31, 2016
Finance

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
BioCentury | Apr 4, 2016
Clinical News

Coagadex regulatory update

...Factor X protein therapy in Factor X-deficient patients ages >=12 (see BioCentury, Oct. 26, 2015). Bio Products Laboratory Ltd....
BioCentury | Feb 8, 2016
Clinical News

Coagadex regulatory update

...Factor X protein therapy in Factor X-deficient patients ages >=12 (see BioCentury, Oct. 26, 2015). Bio Products Laboratory Ltd....
BioCentury | Feb 1, 2016
Company News

Bio Products Laboratory sales and marketing update

...Late last year, Bio Products Laboratory launched Coagadex in the U.S. for on-demand treatment and control of bleeding...
...acquisition cost (WAC) for the plasma-derived Factor X protein therapy is $7.74 per 1 IU. Bio Products Laboratory Ltd....
BioCentury | Jan 30, 2016
Company News

CHMP backs basket of therapies

...treatment last month (see BioCentury Extra, Dec. 22, 2015) . The committee recommended Coagadex from Bio Products Laboratory Ltd....
BioCentury | Oct 26, 2015
Clinical News

Coagadex regulatory update

...An MAA for the plasma-derived Factor X protein therapy is under review in the EU. Bio Products Laboratory Ltd....
Items per page:
1 - 10 of 16